^
    2d
    Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel) (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, Deciphera Pharmaceuticals, LLC
    New P1 trial
    |
    Romvimza (vimseltinib)
    2d
    ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Stephen Shiao | Trial completion date: Dec 2032 --> Jul 2033 | Initiation date: Sep 2025 --> Jun 2026 | Trial primary completion date: Dec 2032 --> Jul 2033
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)
    2d
    Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation (clinicaltrials.gov)
    P2, N=35, Recruiting, Stephen Shiao | Active, not recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Niktimvo (axatilimab-csfr)
    6d
    Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study (clinicaltrials.gov)
    P=N/A, N=500, Active, not recruiting, West China Hospital
    New trial
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    Sulanda (surufatinib)
    6d
    Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial (clinicaltrials.gov)
    P2, N=72, Not yet recruiting, Mayo Clinic | Trial completion date: Jan 2033 --> Jun 2033 | Initiation date: Jan 2026 --> Jun 2026 | Trial primary completion date: Jan 2028 --> Jun 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    cyclophosphamide • Niktimvo (axatilimab-csfr)
    6d
    Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment (clinicaltrials.gov)
    P2, N=15, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    Signatera™
    |
    AMB-05X
    6d
    Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) (clinicaltrials.gov)
    P2, N=20, Recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Not yet recruiting --> Recruiting
    Enrollment open
    |
    pimicotinib (ABSK021)
    7d
    RUNX1 Directly Activates WNT2 to Orchestrate Tumor-Associated Macrophage Reprogramming in Colorectal Cancer. (PubMed, Mol Carcinog)
    In vivo, we evaluated tumor growth (subcutaneous xenografts) and lung metastasis (tail-vein injection) following WNT2 knockdown and performed rescue studies using an IL-10 neutralizing antibody or the CSF1R inhibitor BLZ945...RUNX1 directly activates WNT2 to promote cytokine production and M2 macrophage polarization, thereby accelerating CRC growth and metastasis. These findings suggest that targeting the RUNX1-WNT2 axis and its downstream macrophage programs may offer a therapeutic strategy and potential biomarker framework for CRC.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • RUNX1 (RUNX Family Transcription Factor 1) • IL10 (Interleukin 10) • CCL2 (Chemokine (C-C motif) ligand 2) • CD68 (CD68 Molecule) • MRC1 (Mannose Receptor C-Type 1) • CD86 (CD86 Molecule) • WNT2 (Wnt Family Member 2)
    |
    sotuletinib (BLZ-945)
    13d
    EI-1071-202: A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients (clinicaltrials.gov)
    P2, N=15, Recruiting, Elixiron Immunotherapeutics (Hong Kong) Ltd. | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    14d
    INCA34176-254: A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Incyte Corporation | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Jakafi (ruxolitinib) • prednisone • Niktimvo (axatilimab-csfr)
    16d
    Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment (clinicaltrials.gov)
    P2, N=15, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended
    Trial suspension • Circulating tumor DNA
    |
    Signatera™
    |
    AMB-05X
    16d
    Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML (clinicaltrials.gov)
    P1, N=32, Not yet recruiting, Northside Hospital, Inc.
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation • TP53 deletion
    |
    Venclexta (venetoclax) • decitabine • Niktimvo (axatilimab-csfr)